UROY options demand spikes as shorts pile in

Uranium Royalty Corp. is drawing attention from three directions at once. The stock is down 23% over the past month. Short positions have jumped sharply. Now options traders are reaching for downside protection at a rate rarely seen in this name.

Put-call ratio at a 52-week extreme

The most striking signal is in the options market. UROY's put-call ratio hit 0.37 on 19 October. That is 4.2 standard deviations above its 20-day average of 0.25. The reading is close to the 52-week high of 0.41. In plain terms, demand for puts has surged relative to calls in a single session, and the magnitude of the move is exceptional by this stock's own history.

Short interest climbs sharply

Short interest has risen 37% in one week to 8.72% of the free float, equivalent to roughly 11.65 million shares. Over the past month, short positions have grown by 345%. The official FINRA figure, settling at 30 September, put short shares at 12.1 million with 2.25 days to cover.

One nuance worth noting: availability has simultaneously loosened. Availability now stands at 157%, up 65% week on week. That means lenders have expanded the pool of shares available to borrow. There is no borrow squeeze here. Shorts are building positions in a liquid lending market, not fighting for scarce stock. Cost to borrow has risen 114% over the week to 0.93%, but remains at historically low levels for the name.

An activist holder trimming

Uranium Energy Corp. holds a Schedule 13D activist stake in UROY, as last disclosed on 28 July. Its reported position has fallen from 18.4% to 7.7% of the company's shares. As the disclosure note states, 13D/G positions reflect holdings at the time of filing. A holder dropping below 5% may exit without a further filing. The direction of travel, however, is clear from the data on record.

Russell 2000 candidate adds a mechanical wrinkle

ORTEX puts the probability of UROY joining the Russell 2000 at the December 2026 Semi-Annual Review at 76%. The rank date is 30 October, with announcement expected 13 November and the trade date on 11 December. ORTEX estimates index trackers would need to buy approximately $185 million worth of stock, equivalent to 14.9 days of normal trading volume. The stock is 90.3% above the price threshold that decides eligibility. In past additions of this type (655 precedents), median stock performance from announcement to effective date was minus 4%, with trade-day volume running at 8.8 times normal. That is history, not a forecast.

HC Wainwright reiterated its Buy rating and $4.50 target on 19 October. The stock closed at $3.50, implying roughly 29% upside to consensus. The next earnings date is 11 December.

What to watch: whether the put-call ratio remains elevated into the Russell rank date on 30 October, and whether the activist holder files a further amendment.